Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 10 Results

Title
Intervention Indication Therapeutic Area Year Actions
Enzalutamide (Xtandi) for non-metastatic prostate cancer Enzalutamide (Xtandi; MDV3100) Prostate cancer Male Reproductive Cancer 2017 View  |  Download
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy and/or radiotherapy Enzalutamide (Xtandi; MDV3100) Non-metastatic prostate cancer Male Reproductive Cancer 2022 View  |  Download
Enzalutamide in addition to androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer Enzalutamide (Xtandi; MDV3100) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Nivolumab in combination with rucaparib for chemotherapy naive metastatic castration-resistant prostate cancer Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Nivolumab in combination with rucaparib for metastatic castration-resistant prostate cancer with prior chemotherapy Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Pembrolizumab with Enzalutamide and androgen deprivation therapy for the treatment of metastatic hormone sensitive prostate cancer Androgen deprivation therapy , Enzalutamide (Xtandi; MDV3100) , Pembrolizumab (Keytruda; MK-3475) Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Pembrolizumab with enzalutamide for treating
metastatic castration-resistant prostate cancer
Enzalutamide (Xtandi; MDV3100) , Pembrolizumab (Keytruda; MK-3475) Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Radium-223 dichloride with enzalutamide for treating hormone-relapsed metastatic prostate cancer Enzalutamide (Xtandi; MDV3100) , Radium-223 dichloride Prostate cancer Male Reproductive Cancer 2024 View  |  Download
Talazoparib in addition to enzalutamide for metastatic castration-resistant prostate cancer Enzalutamide (Xtandi; MDV3100) , Talazoparib (MDV3800; BMN-673; Talzenna; talazoparib tosylate) Prostate cancer Male Reproductive Cancer 2021 View  |  Download
Talazoparib with enzalutamide for previously untreated homologous recombination repair-mutated metastatic hormonal-sensitive prostate cancer Enzalutamide (Xtandi; MDV3100) , Talazoparib (MDV3800; BMN-673; Talzenna; talazoparib tosylate) Prostate cancer Male Reproductive Cancer 2024 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications